Practical issues in CAR T-cell therapy

Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen. CAR T-cells are then expanded for clinical use and infused back into the patient's body to attack cancer cells. Although CAR T-cell therapy is considered a major breakthrough in cancer immunotherapy, it is not without limitations. In this review, we discuss the barriers to effective CAR T-cell therapy in Korea.

Automated summary

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary advancement in personalized cancer treatment, where the patient's own T-cells are genetically engineered to target tumor antigens. However, this therapy faces limitations, which are discussed in this review. Specifically, the review focuses on the barriers to effective CAR T-cell therapy in Korea.